In 2026 the global health landscape saw four major moves: the WHO lost the United States as a member, India cleared the way for semaglutide generic production, courts in the US and Europe intensified scrutiny of social‑media impact on youth, and India reviewed its progress toward eliminating malaria. These developments affect public‑health governance, drug affordability, child protection, and disease‑control targets – all core topics for UPSC aspirants.
Key Developments
- The United States formally withdrew from the WHO, citing funding concerns and sovereignty issues.
- India’s drug regulators granted licences to domestic manufacturers to produce generic versions of semaglutide, expanding the obesity‑treatment market in India.
- Judicial and legislative bodies in the United States and Europe began hearings on stricter, enforceable safeguards for children on social‑media platforms.
- India’s National Vector‑Borne Disease Control Programme released a mid‑term review of the malaria‑elimination drive, noting state‑level successes and persistent gaps.
Important Facts
• The US withdrawal became effective on 1 January 2026, removing its annual contribution of roughly US$400 million to the WHO budget.
• Two Indian firms received approval to manufacture semaglutide generics, potentially cutting prices by up to 70 % compared with imported bra